Jazz Pharmaceuticals vs Neurocrine Biosciences
JAZZ and NBIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and NBIX compare
Jazz Pharmaceuticals and Neurocrine Biosciences are about the same size, with market caps of $15.7B and $17.0B.
On earnings, Neurocrine Biosciences is cheaper: it trades at 24.8× trailing earnings, against 78.7× for Jazz Pharmaceuticals.
Neurocrine Biosciences grew revenue faster over the last twelve months (38.0% versus 13.5% for Jazz Pharmaceuticals).
Neurocrine Biosciences keeps more of each dollar of sales as profit, with a net margin of 19.0% compared with 4.4% at Jazz Pharmaceuticals.
Neurocrine Biosciences scores higher on the StockData Score (20 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | NBIX |
|---|---|---|
| Size and price | ||
| Market cap | $15.7B | $17.0B |
| Share price | $241.55 | $167.40 |
| Change, 1 year | 76.7% | 14.0% |
| Change, 5 years | 88.2% | 94.6% |
| Beta (5Y) | 0.53 | 0.46 |
| Employees | 2,890 | 1,800 |
| StockData Score | ||
| Total score | 7 | 20 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 2 | 5 (better) |
| Performance score | 3 | 5 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 78.7× | 24.8× (better) |
| P/S | 3.3× (better) | 4.6× |
| P/B | 3.7× (better) | 4.4× |
| EV/EBITDA | 43.2× | 18.3× (better) |
| P/FCF | 9.7× (better) | 16.4× |
| PEG | – | 0.56 |
| FCF yield | 10.3% (better) | 6.1% |
| Fair value | $110.08 | $190.74 |
| Margin of safety | −119% | 12.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.5% | 38.0% (better) |
| Revenue growth, 5Y average | 12.5% | 22.3% (better) |
| Net income growth (TTM) | – | 64.1% |
| EPS growth (TTM) | – | 61.2% |
| EPS growth, 5Y average | – | 2.3% |
| Profitability | ||
| Gross margin | – | 97.7% |
| Operating margin | 9.0% | 24.0% (better) |
| Net margin | 4.4% | 19.0% (better) |
| FCF margin | 34.4% (better) | 28.1% |
| Return on equity | 5.1% | 20.4% (better) |
| Return on invested capital | 4.5% | 26.6% (better) |
| Financial health | ||
| Debt / equity | 1.33 (better) | 0.00 |
| Net debt / EBITDA | 6.37 | – |
| Current ratio | 1.82 | 2.04 (better) |
| Altman Z-score | 1.97 | 7.44 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.08% |
| Shareholder yield | 0.00% (better) | −0.08% |
| Ownership | ||
| Held by institutions | 99.2% | 99.5% |
| Held by insiders | 3.4% | 1.2% |
| Insider net buying, 12 months | −$67.1M (better) | −$74.4M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 9.3% | 5.9% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- NBIX stock overview
- NBIX income statement
- NBIX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.